FDA lifts clinical hold on Peninsula company’s off-the-shelf cancer cell therapy trial

Three months after regulators halted clinical trials of its experimental off-the-shelf cancer cell therapy, Allogene Therapeutics Inc. said the Food and Drug Administration has lifted the hold. The South San Francisco-based company (NASDAQ: ALLO) said its investigation found that the cell therapy ALLO-501A, Allogene's gene-editing process and its...

Click to view original post